Viola Davis partners with GSK to educate adults 50 and older about their shingles risk

Impact · against what's priced in

GSK's partnership with Viola Davis to increase shingles vaccine awareness is a positive but marginal catalyst. While it aims to drive uptake among adults 50+, celebrity-led awareness campaigns are standard industry practice and unlikely to shift the valuation of a large-cap pharma company significantly.

GSK+0.10

No priced-in read yet

In context

The 'Shingles, actually' campaign utilizes a high-profile partnership with Viola Davis to address the disconnect where healthy adults 50+ underestimate their risk, potentially increasing vaccine revenue from a market with 1 million annual US cases.

Read from the article alone

• public health▲400%
• vaccines▲300%
• healthcare
• GSK
• marketing
• pharma
• shingles

Top 2 movers · tap to explore